Corpus ID: 13577403

Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.

  title={Pharmacological studies with an alkylating narcotic agonist, chloroxymorphamine, and antagonist, chlornaltrexamine.},
  author={T. Caruso and D. L. Larson and P. Portoghese and A. Takemori},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={213 3},
The 6-bis(2)chloroethyl)amino derivatives of oxymorphone and naltrexone, chloroxymorphamine (COA) and chlornaltrexamine (CNA), respectively, produce an irreversible inhibition of [3H]naltrexone binding to mouse brain homogenates. Intracerebroventricular (i.c.v.) injection of COA (4 nmol/mouse) elicits analgesia which lasts 4 times longer than analgesia produced by equimolar and equieffective dose of oxymorphone. The analgesia induced by COA can be reversed and blocked by naloxone. Injections of… Expand
Effects of beta-chlornaltrexamine on food intake, body weight and opioid-induced feeding.
The long duration of the effects of beta-CNA suggests that this compound will be a useful pharmacological tool in further study of the opioid feeding system and could be completely accounted for by the reduction in intake. Expand
Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
M-CAM is a potent, long-lasting, and specific antagonist at mu-receptors in vivo that lacks confounding agonist actions and ex vivo binding assays confirmed themu-receptor selectivity of M-C AM. Expand
Antagonism of morphine-induced behavioral suppression by opiate receptor alkylators
Experiments were conducted to test the in vivo opiate specificity and long-lasting effects of two non-equilibrium opiate antagonists: beta-chlornaltrexamine (beta-CNA) and the beta-fumarate methylExpand
Recovery from opioid receptor alkylation: social conflict analgesia and brain [3H]etorphine binding in beta-chlornaltrexamine-treated mice.
The effects of beta-chlornaltrexamine (CNA, 5 mg/kg s.c.) on social conflict analgesia and brain opioid binding were investigated in mice at different times after the administration of the alkylatingExpand
Long-term effects of neonatal exposure to isobutylmethylxanthine
The results indicate that exposure to a methylxanthine, and thus quasi-morphine withdrawal, during development results in long-lasting alterations of a system which is involved in opioid withdrawal. Expand
Long-term effects of neonatal exposure to isobutylmethylxanthine
The use of IBMX in developing rats may also offer a model for studying the long-term consequences of the expression of opioid withdrawal during the neonatal period, since this agent induces a quasi-morphine withdrawal syndrome (QMWS) in mature rats. Expand
The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.
The fumaramate methyl ester derivatives of naltrexone and oxymorphone were both found to be reversible agonists on the guinea pig ileal longitudinal muscle preparation but beta-FNA possessed on irreversible antagonistic effect against morphine whereas beta-FOA had no such capacity. Expand
Reduction in opiate receptor reserve in morphine tolerant guinea pig ilea.
Ilea from guinea pigs made tolerant by chronic morphine pellet implantation were found to be more sensitive to the effects of CNA treatment; there was a reduction in the number of spare receptors for normorphine. Expand
Spinal antagonism of tolerance and dependence induced by systemically administered morphine.
The spinal cord plays a significant role in development of tolerance and dependence induced by systemically administered opiates, and treatment with beta-CNA before morphine treatment antagonized naloxone-induced expression of withdrawal. Expand
Chapter 3. Analgesics (Peripheral and Central), Endogenous Opioios and Their Receptors
Study related to the development of new and improved analgesics has proceeded forward on several different fronts and there is now overwhelming evidence for the presence of two distinct populations of opioid receptors, the p-(morphine) receptor and the 6-(enkephalin) receptor, and good evidence for a third receptor, the K-receptor. Expand